Trial Profile

A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Itraconazole (Primary) ; Paroxetine (Primary) ; PM-8002 (Primary) ; YL-202 (Primary)
Indications Acral lentiginous melanoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; HER2 negative breast cancer; Liver cancer; Neuroendocrine carcinoma; Non-small cell lung cancer; Pancreatic ductal carcinoma; Renal cell carcinoma; Skin cancer; Solid tumours; Uveal melanoma
Focus Adverse reactions; Therapeutic Use
Sponsors BioNTech

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com